Karo Pharma AB logo

KARO - Karo Pharma AB Share Price

SEK54 -0.1  -0.2%

Last Trade - 16/04/21

Mid Cap
Market Cap £1.03bn
Enterprise Value £1.49bn
Revenue £247.3m
Position in Universe 324th / 1831
Unlock KARO Revenue
Relative Strength (%)
1m +2.68%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -28.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
69.1 347.3 657.6 1,615 1,901 2,883 3,069 3,161 +110.9%
-96.4 +9,283 -91.6 +43.7 +345.5 +6.67
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, KaroPharma AB revenues increased 52% to SEK2.88B. Net incomeincreased from SEK8.9M to SEK82M. Revenues reflect Europesegment increase from SEK223.2M to SEK712M, Sweden segmentincrease of 41% to SEK848.8M. Net income benefited fromOther operating income/expenses - Balanc decrease fromSEK23.6M (expense) to SEK5.9M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for KARO
Graphical History


KARO Revenue Unlock KARO Revenue

Net Income

KARO Net Income Unlock KARO Revenue

Normalised EPS

KARO Normalised EPS Unlock KARO Revenue

PE Ratio Range

KARO PE Ratio Range Unlock KARO Revenue

Dividend Yield Range

KARO Dividend Yield Range Unlock KARO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
KARO EPS Forecasts Unlock KARO Revenue
Profile Summary

Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer treatment; ERbeta multiple sclerosis (MS), which specializes in the autoimmune disease MS treatment; and Related Orphan Receptor Gamma (RORgamma), which is responsible for the nuclear receptors application in treatment of autoimmune disease, such as rheumatoid arthritis and psoriasis. The Company collaborates with Pfizer, 4D Science, and Merck, among others. Its trademarks portfolio includes Karo Bio, BioKey, BioKey Assay and Molecular Braille. The Company operates Karo Bio Research AB, Karo Bio Discovery AB, Kommanditbolaget Odenplan Fastigheter, Tanomed AB, MedCore AB and Medireduce AB as subsidiaries.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since April 3, 1998
No. of Shareholders: 7,940
No. of Employees: 243
Sector Healthcare
Industry Pharmaceuticals
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 223,093,515
Free Float (0.0%)
Eligible for
KARO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for KARO
Upcoming Events for KARO
Wednesday 21st April, 2021
Q1 2021 Karo Pharma AB Earnings Release
Wednesday 21st April, 2021
Karo Pharma AB Annual Shareholders Meeting
Thursday 22nd July, 2021
Q2 2021 Karo Pharma AB Earnings Release
Frequently Asked Questions for Karo Pharma AB
What is the Karo Pharma AB share price?

As of 16/04/21, shares in Karo Pharma AB are trading at SEK54, giving the company a market capitalisation of £1.03bn. This share price information is delayed by 15 minutes.

How has the Karo Pharma AB share price performed this year?

Shares in Karo Pharma AB are currently trading at SEK54 and the price has moved by -2.35% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Karo Pharma AB price has moved by -24.33% over the past year.

What are the analyst and broker recommendations for Karo Pharma AB?

Of the analysts with advisory recommendations for Karo Pharma AB, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Karo Pharma AB is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Karo Pharma AB next release its financial results?

Karo Pharma AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Karo Pharma AB dividend yield?

Karo Pharma AB does not currently pay a dividend.

Does Karo Pharma AB pay a dividend?

Karo Pharma AB does not currently pay a dividend.

When does Karo Pharma AB next pay dividends?

Karo Pharma AB does not currently pay a dividend.

How do I buy Karo Pharma AB shares?

To buy shares in Karo Pharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Karo Pharma AB?

Shares in Karo Pharma AB are currently trading at SEK54, giving the company a market capitalisation of £1.03bn.

Where are Karo Pharma AB shares listed? Where are Karo Pharma AB shares listed?

Here are the trading details for Karo Pharma AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: KARO
What kind of share is Karo Pharma AB?

Based on an overall assessment of its quality, value and momentum, Karo Pharma AB is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Karo Pharma AB share price forecast 2021?

Shares in Karo Pharma AB are currently priced at SEK54. At that level they are trading at 1.85% discount to the analyst consensus target price of 0.00.

Analysts covering Karo Pharma AB currently have a consensus Earnings Per Share (EPS) forecast of 2.4 for the next financial year.

How can I tell whether the Karo Pharma AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Karo Pharma AB. Over the past six months, the relative strength of its shares against the market has been -33.59%. At the current price of SEK54, shares in Karo Pharma AB are trading at -7.18% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Karo Pharma AB PE Ratio?

The Karo Pharma AB PE ratio based on its reported earnings over the past 12 months is 0.100k. The shares are currently trading at SEK54.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Karo Pharma AB?

Karo Pharma AB's management team is headed by:

Hakan Astrom - IND
Carl Lindgren - VBD
Bo Hansen - CHM
Erika Henriksson - DRC
Vesa Koskinen - DRC
Christoffer Lorenzen - CEO
Eva Saers - IND
Flemming Ornskov - IND
Jon Johnsson - CFO
Lisa Westerdahl - VPR
Magnus Nylen - OTH
Jonathan Kimber - VOP
Sofia Pedersen - VPR
Anna Elmblad - VPR
Hadi Ghane - OTH
Who are the major shareholders of Karo Pharma AB?

Here are the top five shareholders of Karo Pharma AB based on the size of their shareholding:

EQT Partners AB Private Equity
Percentage owned: 69.4% (114.0m shares)
Avanza Bank Holding AB Corporation
Percentage owned: 2% (3.29m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 0.94% (1.55m shares)
Statens Pensjonsfond Utland Mutual Fund
Percentage owned: 0.94% (1.55m shares)
SEB Investment Management AB Investment Advisor
Percentage owned: 0.7% (1.15m shares)
Similar to KARO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.